Wednesday, June 28, 2006

Promising data for Celtic Pharma's drug addiction treatment

Celtic Pharma's novel immunotherapy vaccine for the treatment of cocaine addiction, TA-CD, has posted encouraging preliminary data in two phase II trials sponsored by the National Institute on Drug Abuse. The first study was a phase IIa study of TA-CD conducted by Dr Margaret Haney, associate professor of Clinical Neuroscience at Columbia University. The study looked at the impact of vaccinating chronic cocaine-dependent volunteers who were not actively seeking to reduce or stop their cocaine use. .

Read More